AI-generated summary
The authors report a prospective study of 62 women with drug-resistant recurrent vulvovaginal candidiasis who received 10 weekly sessions of antimicrobial blue light therapy. Overall symptoms improved in 79% immediately after treatment and in 58% at 6 months, and the authors conclude the therapy was effective. The study had no control group.
- Participants
- 62
- Who or what was studied
- Women with drug-resistant recurrent vulvovaginal candidiasis (four or more episodes in 12 months) who did not respond to standard azole therapy
- Limits stated in the abstract
- The abstract describes a single prospective study without a control group, so the reported improvement cannot be attributed to the therapy alone.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Light-emitting diode. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.